The effects of regimes on harvesting autologous peripheral stem cells with CD34(+) Ö.Ş. Balçik, S. Dagdas, S.K. Güler, G. Özet, A. Oymak, Z. Çelik, N. Zengin, B. Öksüzoglu, M. Ayli, S. Dinçer, M. Albayrak

Turkiye Klinikleri Tıp Bilimleri Dergisi 2008: 28: 640–647 Despite the regimens of harvesting peripheral stem cell vary from one center to another, the most common ones are growth factor plus chemotherapy or growth factor alone. In this study, it was aimed to determine which regimens of harvesting peripheral stem cells having CD34(+) molecular markers were more effective. A retrospective study was done between March 2004 and June 2007, 66 cases were selected for the autologous peripheral stem cell harvesting program in Ankara Numune Hospital Bone Marrow Transplantation Unit. The patients were diagnosed either with Hodgkin’s disease, non-Hodgkin lymphoma, multiple myeloma, or testis germ cell tumor. Regarding harvesting regimes, 41 cases were administered with a combination of cyclophosphamid, etoposide and filgrastim 5 μg/kg/day (CEF); 7 cases with cyclophosphamid and filgrastim 5 μg/kg./day (CF); and 18 cases with filgrastim 10 μg/kg/day alone (F). In the CEF, CF and F groups, the median duration of filgrastim treatment before harvesting CD34(+) cells was 5, 10 and 5 days respectively. The difference was statistically significant between the CEF-F and CF-F groups in terms of the duration of filgrastim treatment before harvesting CD34(+) cells (p< 0.01). The median number of CD34(+) cell apheresis was 1, 2 and 2 in the CEF, CF and F groups, respectively. The difference between the CEF and F groups (p< 0.001) regarding the number of apheresis was also significant. In the CEF, CF and F groups, the median number of harvested CD34(+) cells were 7.36 x 106/kg, 3.4 x 106/kg and 4.1 x 106/kg, respectively. The differences between the CEF-CF and CEF-F groups were statistically significant (p= 0.004 and p< 0.001). It was concluded that a higher number of CD34(+) cells can be harvested with the CEF regimen when compared to the CF and F regimens. Filgrastim 10 μg/kg/day can enhance harvesting an adequate number of CD34(+) cells despite the requirement for more apheresis procedures.

REHA KISNISCI